Currently, there are 37.88M common shares owned by the public and among those 35.05M shares have been available to trade.
Insiders at the company have transacted a total of 16 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 16 of these insider trades were purchases, accounting for 132,068 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
However, the script later moved the day high at 3.8450, down -2.19%. The company’s stock has a 5-day price change of 7.83% and 125.16% over the past three months. ATHA shares are trading 47.33% year to date (YTD), with the 12-month market performance up to 7.83% higher. It has a 12-month low price of $1.33 and touched a high of $3.73 over the same period. ATHA has an average intraday trading volume of 345.46K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 12.86%, 29.93%, and 44.20% respectively.
Institutional ownership of Athira Pharma Inc (NASDAQ: ATHA) shares accounts for 56.43% of the company’s 37.88M shares outstanding.
It has a market capitalization of $136.22M and a beta (3y monthly) value of 2.83. The earnings-per-share (ttm) stands at -$3.18. Price movements for the stock have been influenced by the stock’s volatility, which stands at 7.50% over the week and 6.65% over the month.
Analysts forecast that Athira Pharma Inc (ATHA) will achieve an EPS of $Alterity Therapeutics Limited for the current quarter, $2.04 for the next quarter and $Stocks for Type. The lowest estimate earnings-per-share for the quarter is $ATHABASCA OIL CORP while analysts give the company a high EPS estimate of $Athira Pharma, Inc. Comparatively, EPS for the current quarter was $Autohome Inc. a year ago. Earnings per share for the fiscal year are expected to decrease by -31.62%, and -3.48% over the next financial year.
Looking at the support for the ATHA, a number of firms have released research notes about the stock. JMP Securities stated their Mkt Outperform rating for the stock in a research note on October 17, 2022, with the firm’s price target at $20.
